DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Stock Rated "Hold" by Sell-Side Analysts

Key Points

• Analysts rate DENTSPLY SIRONA “Hold” on average: Of 14 analysts, three recommend selling, eight recommend holding, and three recommend buying. The average 12-month price target is $13.31.
• Institutional ownership is substantial: Hedge funds and other institutional investors own 95.70% of the company, with BlackRock and Southpoint Capital among investors that recently established positions.
• Shares opened at $9.40, near their 52-week low: The stock remains below its 50-day and 200-day moving averages. In its latest quarter, DENTSPLY SIRONA beat EPS and revenue estimates, but revenue declined 4.1% year over year and the company reported a negative net margin.

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report) have earned an average recommendation of "Hold" from the fourteen ratings firms that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $13.31.

A number of brokerages have issued reports on XRAY. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of DENTSPLY SIRONA in a research report on Monday, August 3rd. BMO Capital Markets dropped their price target on shares of DENTSPLY SIRONA from $13.00 to $10.00 and set a "market perform" rating on the stock in a research report on Thursday, September 17th. Barclays boosted their price objective on shares of DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an "underweight" rating in a research note on Monday, August 24th. Barrington Research set a $15.00 target price on shares of DENTSPLY SIRONA in a research note on Monday, August 10th. Finally, Piper Sandler lifted their target price on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a "neutral" rating in a report on Wednesday, July 29th.

Institutional Investors Weigh In On DENTSPLY SIRONA

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth about $283,405,000. Southpoint Capital Advisors LP acquired a new stake in DENTSPLY SIRONA in the 1st quarter valued at approximately $116,000,000. Armistice Capital LLC grew its holdings in DENTSPLY SIRONA by 27.2% in the 4th quarter. Armistice Capital LLC now owns 7,298,000 shares of the medical instruments supplier's stock valued at $83,416,000 after buying an additional 1,562,000 shares during the last quarter. Invenomic Capital Management LP increased its position in DENTSPLY SIRONA by 17.9% in the 4th quarter. Invenomic Capital Management LP now owns 5,132,036 shares of the medical instruments supplier's stock worth $58,659,000 after buying an additional 780,837 shares during the period. Finally, Edmond DE Rothschild Holding S.A. bought a new position in DENTSPLY SIRONA in the 2nd quarter worth approximately $47,780,000. 95.70% of the stock is owned by institutional investors and hedge funds.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ:XRAY opened at $9.40 on Friday. DENTSPLY SIRONA has a fifty-two week low of $9.29 and a fifty-two week high of $14.76. The business has a 50-day moving average of $11.53 and a two-hundred day moving average of $11.36. The stock has a market capitalization of $1.87 billion, a P/E ratio of -3.42, a P/E/G ratio of 1.20 and a beta of 0.84. The company has a debt-to-equity ratio of 1.48, a current ratio of 1.63 and a quick ratio of 1.07.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.17. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The business had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. During the same quarter in the prior year, the firm posted $0.52 EPS. The firm's revenue for the quarter was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts predict that DENTSPLY SIRONA will post 1.4 EPS for the current fiscal year.

About DENTSPLY SIRONA

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental laboratories, and other oral health professionals with solutions spanning preventive, restorative, endodontic, orthodontic, implant, and prosthetic dentistry.

Its portfolio includes dental consumables, equipment and treatment centers, imaging systems, CAD/CAM systems, instruments, dental materials, implants, orthodontic products, and software and digital workflow solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.